A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
brief summary
This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd antibody-drug conjugates (ADC) in participants with advanced solid tumors.
detailed description
This is a 2-part study of valemetostat in combination with DXd ADCs in participants with human epidermal growth factor 2 (HER2)-positive gastric cancer, non-squamous non-small cell lung cancer (NSCLC), or unresectable or metastatic HER2 low breast cancer. The study will begin with a Part 1 Dose-escalation Phase and will continue until the recommended dose for expansion "RDE" of valemetostat is determined and will then be followed by a Part 2 Dose-expansion Phase to further evaluate the safety and tolerability of the combination.
official title
A Phase 1b, Multicenter, Open-Label Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors